FDA Approved: RISEDRONATE SODIUM — Supplemental Application (Teva Pharmaceuticals USA, Inc.)

View source ↗

Summary

FDA approved a supplemental application for risendronate sodium from Teva, indicating labeling changes to the generic product.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Osteoporosis
• Paget Disease of Bone

Drugs mentioned

• RISENDRONATE SODIUM (risendronate sodium)

Snippet

SUPPL AP for RISEDRONATE SODIUM (RISEDRONATE SODIUM)